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iagnosing Subtle
orms of Potentially
ife-Threatening Diseases*
avid J. Callans, MD, FACC
hiladelphia, Pennsylvania
ithin the first few months of my practice, I changed the
ife of a young physician referred for right ventricular (RV)
utflow tract ventricular tachycardia (VT) with the diagno-
is of arrhythmogenic right ventricular cardiomyopathy/
ysplasia (ARVC/D). This was an uncomfortable moment,
ut not one nearly as bad as “the cardiologist’s worst
ightmare” (1), making the opposite mistake of missing a
ife-threatening diagnosis due to mimicking of a much more
ommon benign condition. How often do we make that
istake? Can it be prevented?
See page 731
Since the initial description of ARVC/D, significant
rogress in the understanding of all aspects of this disease
rocess has occurred. Improvements in noninvasive diagno-
is strategies have been a key feature of this progress,
ventually leading to the establishment of formal diagnostic
riteria (2). This has led to more uniform discussion of
atients with similar disease severity and has facilitated
linical discussions of risk in individual patients. Nonethe-
ess, concern has persisted about detection of more subtle
orms or “latent phase” ARVC/D, where the lack of
ignificant RV structural abnormalities may preclude formal
iagnosis but arrhythmic risk may be present.
The use of electrophysiological rather than RV imaging
echniques to evaluate the diagnosis and the arrhythmia
rognosis of patients who may have ARVC/D is a logical
ext step. In previous work by the same group, the use of
V voltage mapping was investigated in a series of 31
atients who met task force criteria for the diagnosis of
RVC/D (3). In 20 patients, detailed mapping demon-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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cientific.trated low-voltage areas that corresponded to wall motion
bnormalities and were associated with fibrofatty replace-
ent on biopsy and a family history of ARVC/D. However,
1 patients had no RV endocardial voltage abnormalities.
his finding was associated with nonfamilial disease, in-
ammatory findings on biopsy, and a good prognosis.
In this issue of the Journal, Corrado et al. (4) report the
esults of a similar invasive evaluation in 27 patients with
ormal RV function and right ventricular outflow tract
RVOT) ventricular arrhythmias. This group was selected
rom a larger population of 89 patients with RVOT tachy-
ardias on the basis of 1 or more high-risk characteristics: a
amily history of early sudden death, competition in com-
etitive athletics (because of the possible association of
ggressive aerobic exercise and RV dysplasia), pre-syncope,
RS duration in the precordial leads 110 ms, presence of
ate potentials on signal-averaged electrocardiography, or
nverted T waves (only observed in the inferior and not in
he anterior precordial leads in this experience). Impor-
antly, none of these patients satisfied task force require-
ents for a diagnosis of ARVC/D before invasive study.
etailed RV electroanatomical mapping (187  29 sites),
rogrammed stimulation, and endomyocardial biopsy were
erformed in all patients. Catheter ablation was performed
n 20 patients, guided by activation and pace mapping, and
as acutely successful in 18 of 20.
Seven patients had at least 1 area in the RV marked by
ow-voltage bipolar electrograms (0.5 mV) with prolonged
urations and delayed components. Abnormal voltage areas
ere seen in the anterior portion of the infundibular free wall
n all patients; additional areas were observed in the apical and
nferior basal free wall in 2 patients. Ventricular tachycardia
as induced with programmed stimulation in 5 of 7 patients,
nd pace mapping or activation mapping localized sites of
rigin to the free wall sites of abnormal voltage. Six of these
atients had abnormal RV apical free wall endomyocardial
iopsies, demonstrating fibrofatty myocyte replacement. Pa-
ients with voltage abnormalities were more likely to have
recordial QRS prolongation, inducible VT with programmed
timulation, and positive signal-averaged electrocardiograms.
blation was acutely successful in 4 of 5 patients; 2 of the
atients with apparently successful and 1 with an unsuccessful
blation procedure had life-threatening ventricular arrhythmias
n the 41  8-month follow-up. These patients received
mplantable defibrillators and had subsequent appropriate
herapies.
In contrast, 20 patients had normal RV voltage mapping.
one of these patients had positive endomyocardial biop-
ies. Arrhythmias in this group were unlikely to be induced
ith programmed stimulation (as opposed to isoproterenol
nfusion) and typically arose from the septal aspect of the
VOT. None of these patients had adverse outcomes in
ollow-up, although 7 had recurrent ventricular arrhythmias
1 patient after an unsuccessful ablation attempt, 6 who did
ot have ablation).
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February 19, 2008:740–1 Editorial CommentThe authors make several conclusions from these obser-
ations. First, voltage mapping appears to be an effective
ay of distinguishing early or concealed ARVC/D from
diopathic VT. Second, even in this concealed phase of the
isease, significant electrical abnormalities may be present,
ith attendant risk of life-threatening ventricular arrhyth-
ias in intermediate-term follow-up. Most electrophysiolo-
ists rely on structural assessment of the RV or electrocar-
iogram findings to exclude a diagnosis of ARVC/D,
therwise reserving invasive evaluation for patients with
ymptoms that would justify an ablation procedure. The
ifficulties with identification of RV fatty infiltration by
agnetic resonance imaging are appreciated (5); however,
s we are accustomed to thinking that arrhythmia risk
ollows the advent of ventricular dysfunction with LV disease,
he absence of significant RV enlargement or motion abnor-
alities had been reassuring before this report.
This begs the question: what should the appropriate gold
tandard be for evaluating the strategy of voltage mapping?
oltage mapping certainly seemed to outperform imaging
nd electrocardiographic criteria in the present study. Al-
hough cardiac magnetic resonance imaging was not an
mportant part of this evaluation, subtle abnormalities were
bserved just as often in both groups. The correlation with
iopsy findings in both studies is impressive. Although one
ould wonder about the rare outlier (how should the patient
ith the abnormal voltage map and the negative biopsy be
onsidered?), the risk associated with an abnormal voltage
ap was fairly high in both studies and is not well predicted
y the results of programmed stimulation or apparently
uccessful catheter ablation.
The recent observations that epicardial voltage abnormal-
ties may be more extensive than endocardial, at least in
atients with less subtle forms of the disease, adds another
imension to the uncertainty (6).
The authors admit that extension of these results to the
eneral population of young patients with RVOT tachycar-
ias is not possible. This group all had some aspect of risk,
nd the proportion of abnormal voltage maps in an un-
elected population is likely to be much lower. In addition,
he incidence of ARVC/D is higher in the Veneto region
han would be expected elsewhere. Furthermore, it is likely
hat all ARVC/D is not the same. Experiences comparing
uropean and U.S. patients suggest differences in the
roportion of familial/sporadic incidence, prognosis, and
ause of death (i.e., proportion of sudden death vs. progres-
ive heart failure) (7–10). The beginnings of genetic diag-
osis also document many subtypes with an apparently
imilar phenotype. All of this underscores the importance of
egistries tracking the variations of this disease in largeumbers of patients over longer periods of time to allow
ppropriate distinctions to be made (11,12).
The authors are to be congratulated for this important
ontribution, which will have considerable clinical impact.
nfortunately, this study underscores the treacherous and
ifficult nature of diagnosing serious threats to young,
pparently normal patients.
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f Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania
9104. E-mail: david.callans@uphs.upenn.edu.
EFERENCES
1. Viskin S, Antzelevitch C. The cardiologist’s worst nightmare: sudden
death from benign ventricular arrhythmias. J Am Coll Cardiol 2005;
46:1295–7.
2. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic
right ventricular dysplasia/cardiomyopathy. Task Force of the Work-
ing Group Myocardial and Pericardial Disease of the European
Society of Cardiology and of the Scientific Council on Cardiomyop-
athies of the International Society and Federation of Cardiology. Br
Heart J 1994;71:215–8.
3. Corrado D, Basso C, Leoni L, et al. Three-dimensional electroana-
tomic voltage mapping increases accuracy of diagnosing arrhythmo-
genic right ventricular cardiomyopathy/dysplasia. Circulation 2005;
111:3042–50.
4. Corrado D, Basso C, Leoni L, et al. Three-dimensional electroana-
tomical voltage mapping and histologic evaluation of myocardial
substrate in right ventricular outflow tract tachycardia. J Am Coll
Cardiol 2008;51:731–9.
5. Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance imaging
of arrhythmogenic right ventricular dysplasia: sensitivity, specificity,
and observer variability of fat detection versus functional analysis of the
right ventricle. J Am Coll Cardiol 2006;48:2277–84.
6. Garcia FC, Sussman JS, Bala R, et al. Epicardial ablation to eliminate
ventricular tachycardia associated with right ventricular cardiomyopa-
thy: characterization of the substrate (abstr). Heart Rhythm 2007;3:
S4–5.
7. Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ. Long-
term follow-up in patients with arrhythmogenic right ventricular
disease. Eur Heart J 1989;10 Suppl D:68–73.
8. Hulot J-S, Jouven X, Emapna J-F, Frank R, Fontaine G. Natural
history and risk stratification of arrhythmogenic right ventricular
dysplasia/cardiomyopathy. Circulation 2004;100:1879–84.
9. Marchlinski FE, Zado E, Dixit S, et al. Electroanatomic substrate and
outcome of catheter ablative therapy for ventricular tachycardia in
setting of right ventricular cardiomyopathy. Circulation 2004;110:
2293–8.
0. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular
dysplasia: a United States experience. Circulation 2005;112:3823–32.
1. Marcus F, Towbin JA, Zareba W, et al., ARVD/C Investigators.
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/
C): a multidisciplinary study: design and protocol. Circulation 2003;
107:2975–8.
2. Basso C, Wichter T, Danieli GA, et al. Arrhythmogenic right
ventricular cardiomyopathy: clinical registry and database, evaluation
of therapies, pathology registry, DNA banking. Eur Heart J 2004;25:
531–4.
